COMMUNIQUÉS West-GlobeNewswire

FRDJ salue la décision de l’ARC de revoir les refus des demandes pour le diabète

11/12/2017 - 15:33

TORONTO, 11 déc. 2017 (GLOBE NEWSWIRE) -- Les plus de 300 000 Canadiens et leur famille qui vivent avec le diabète de type 1 (DT1) au pays se réjouissent de l’annonce faite aujourd’hui du gouvernement du Canada et de l’ [...]

Salvis Lapins Will Remain of Olainfarm’s Management Board

11/12/2017 - 15:20

Olaine, 2017-12-11 15:20 CET (GLOBE NEWSWIRE) -- “I have very strong ties with Olainfarm. They have matured during more than a decade, during which we had our reasons for celebrations and we have coped with quite a few [...]

Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference

11/12/2017 - 15:05

WESTLAKE VILLAGE, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of [...]

Aptevo Therapeutics’ Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples

11/12/2017 - 15:02

New APVO436 Preclinical Data Show Robust T-Cell Engagement and Cytotoxicity in AML Patient Specimens SEATTLE, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO ), a biotechnology company focused [...]

Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium

11/12/2017 - 15:00

Supinoxin enhances the efficacy of immunotherapy in multiple preclinical models Supinoxin shows potent activity against patient-derived triple negative breast cancer (TNBC) tumors in preclinical models Supinoxin is [...]

Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders

11/12/2017 - 15:00

NORCROSS, Ga., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, announced today that the Company will present a corporate [...]

Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura

11/12/2017 - 14:30

HAYWARD, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ) today announced a positive outcome of the pre-specified interim futility analysis for the RESULT Phase 3 clinical study of [...]

ToolGen, Inc. Demonstrates Potential of CRISPR/cas9 Gene Editing to Overcome T-Cell Immunosuppression

11/12/2017 - 14:30

Potential Therapeutic Strategy to Target Tumors that Evade T-Cell Immune Response Data Presented at the 59 th American Society of Hematology Annual Meeting SEOUL, South Korea, Dec. 11, 2017 (GLOBE NEWSWIRE) -- ToolGen, [...]

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors

11/12/2017 - 14:15

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV ), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]

Restoration Robotics® Announces Appointment of Mark Hair as Chief Financial Officer

11/12/2017 - 14:01

SAN JOSE, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Restoration Robotics, Inc. (NASDAQ: HAIR ), announced today that Mark L. Hair will join the Company as Chief Financial Officer, effective January 5, 2018. Mr. Hair [...]

Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial

11/12/2017 - 14:00

145 Patients to be enrolled Data expected in the second quarter of 2018 Study will be fully-funded by BARDA GAITHERSBURG, Md., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT ), a clinical-stage [...]

TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology

11/12/2017 - 14:00

MENLO PARK, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- TeneoBio, Inc. yesterday presented preclinical data on its lead therapeutic candidate, TNB-383B, a multivalent anti-BCMAxCD3 at the American Society of Hematology [...]

Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting

11/12/2017 - 14:00

SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced [...]

Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development

11/12/2017 - 14:00

PLYMOUTH MEETING, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) has promoted Dr. Laurent Humeau to Senior Vice President, Research & Development, reporting to Dr. J. Joseph Kim, [...]

HempAmericana Commences Distributor Agreement Negotiations with Major CBD Oil Distributors

11/12/2017 - 14:00

NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- HempAmericana, Inc. (OTC:HMPQ) (the “Company”) is excited to announce it has begun negotiations with high-volume CBD Oil distributors around the country. The company is [...]

Yield10 Bioscience Grants Research License to Monsanto to Evaluate Two Novel Yield Traits in Soybean

11/12/2017 - 14:00

WOBURN, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN ) announced today that it has granted a non-exclusive research license to Monsanto Company to evaluate its novel C3003 and C3004 [...]

Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

11/12/2017 - 14:00

Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN FRANCISCO, Calif., Dec. 11, [...]

Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors

11/12/2017 - 14:00

SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announced the dosing of the first cancer patient in its Phase 1 trial of SM08502, a small molecule Wnt pathway inhibitor in oral tablet formulation. This [...]

Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis

11/12/2017 - 14:00

Eight of 12 patients (67 percent) with cardiac involvement responded to therapy with a median time to cardiac response of 21 days 14 of 24 (63 percent) of patients demonstrated organ response CAEL-101 dosed once weekly [...]